Your browser doesn't support javascript.
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting.
Abu-Raddad, Laith J; Chemaitelly, Hiam; Malek, Joel A; Ahmed, Ayeda A; Mohamoud, Yasmin A; Younuskunju, Shameem; Ayoub, Houssein H; Al Kanaani, Zaina; Al Khal, Abdullatif; Al Kuwari, Einas; Butt, Adeel A; Coyle, Peter; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul Rahim, Hanan F; Yassine, Hadi M; Al Kuwari, Mohamed G; Al Romaihi, Hamad Eid; Al-Thani, Mohamed H; Bertollini, Roberto.
  • Abu-Raddad LJ; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Chemaitelly H; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation, Education City, Doha, Qatar.
  • Malek JA; Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.
  • Ahmed AA; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Mohamoud YA; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation, Education City, Doha, Qatar.
  • Younuskunju S; Genomics Laboratory, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Ayoub HH; Department of Genetic Medicine, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Al Kanaani Z; Genomics Laboratory, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Al Khal A; Genomics Laboratory, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Al Kuwari E; Genomics Laboratory, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Butt AA; Department of Mathematics, Statistics, and Physics, Qatar University, Doha, Qatar.
  • Coyle P; Hamad Medical Corporation, Doha, Qatar.
  • Jeremijenko A; Hamad Medical Corporation, Doha, Qatar.
  • Kaleeckal AH; Hamad Medical Corporation, Doha, Qatar.
  • Latif AN; Hamad Medical Corporation, Doha, Qatar.
  • Shaik RM; Hamad Medical Corporation, Doha, Qatar.
  • Abdul Rahim HF; Hamad Medical Corporation, Doha, Qatar.
  • Yassine HM; Hamad Medical Corporation, Doha, Qatar.
  • Al Kuwari MG; Hamad Medical Corporation, Doha, Qatar.
  • Al Romaihi HE; Hamad Medical Corporation, Doha, Qatar.
  • Al-Thani MH; College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • Bertollini R; Biomedical Research Center, Qatar University, Doha, Qatar.
Clin Infect Dis ; 73(7): e1830-e1840, 2021 10 05.
Article in English | MEDLINE | ID: covidwho-1455275
ABSTRACT

BACKGROUND:

Risk of reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. We assessed the risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirmed cases in Qatar.

METHODS:

All SARS-CoV-2 laboratory-confirmed cases with at least 1 polymerase chain reaction-positive swab that was ≥45 days after a first positive swab were individually investigated for evidence of reinfection. Viral genome sequencing of the paired first positive and reinfection viral specimens was conducted to confirm reinfection.

RESULTS:

Out of 133 266 laboratory-confirmed SARS-CoV-2 cases, 243 persons (0.18%) had at least 1 subsequent positive swab ≥45 days after the first positive swab. Of these, 54 cases (22.2%) had strong or good evidence for reinfection. Median time between the first swab and reinfection swab was 64.5 days (range, 45-129). Twenty-three of the 54 cases (42.6%) were diagnosed at a health facility, suggesting presence of symptoms, while 31 (57.4%) were identified incidentally through random testing campaigns/surveys or contact tracing. Only 1 person was hospitalized at the time of reinfection but was discharged the next day. No deaths were recorded. Viral genome sequencing confirmed 4 reinfections of 12 cases with available genetic evidence. Reinfection risk was estimated at 0.02% (95% confidence interval [CI], .01%-.02%), and reinfection incidence rate was 0.36 (95% CI, .28-.47) per 10 000 person-weeks.

CONCLUSIONS:

SARS-CoV-2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid